博安生物2023中期报告

: 6955 2013T-cellEngagerADCT ®(BA1101)®(BA6101)11BA1102®BA9101®BA5101®BA1104®IIIBA6101BA1102IIIBLA 7BA1105ADCCClaudin 18.2BA1106CD25BA1301ADCBA21014IL-4RBA1202CEA/CD3 T-cellEngagerADC20236 303045 BA-huMab®T-cell Engager(ADC)ADC CMCGMP ®2,000®® 1477BA9101® 39 39 3485 FCGHKFCG H 183171712–1716 9 100020118 97927 6955 www.boan-bio.com Bank of AmericaCitibank N.A., Singapore Branch 1. 20236 30261.22022630220.740.518.4%®(BA1101) 2. 20236 30103.039.4%20226 3033.3%20236 302023 3. 20236 30158.220226 3010.97.4% 4. 20236 30117.120226 30100.816.316.2% 5. 20236 30126.0202263043.12022III 2013T-cell EngagerADC T 2023 ®®202263018.4%261.220231®®®20231 10®® 2023BLA20233BA1102®(Agência Nacional de Vigilância Sanitária)ANVISAIII20233BA9101III20235BA5101IIIBA6101BA1102III20235FPIBA11042023 8III4BA1106BA2101 BA1301BA1202I 20236 30285202372 8,000L1,700L2*500L3*2,000L 20233 1320234 19BBA 2023 ®VEGF®20214 •20231®2®5 •20234ANVISA® ®RANKG2®202211 •20231®®® •20235BA6101BA1102IIIFPI BA1102RANKG2® BA1102®RANKG2RANKLOPG/RANKL/RANKGCTB1≥45kg •20233BA1102 •20235BA6101BA1102IIIFPI BA9101® (VEGFR)VEGFR1 Ig2VEGFR2 Ig3IgG1FcVEGF-AVEGF-B PlGFVEGFVEGF-APlGF®Eylea®2011(wAMD)(RVO)(DME)(DR)(ROP)2018wAMDDME •20233BA9101III202010BA9101 III1477.HKBA9101BA9101BA9101 BA5101-1 (GLP-1)® -1 (GLP-1)11HbA1c11BA5101 •20235BA5101III BA1105Claudin 18.2IgG1 Claudin 18.2BA1105Claudin 18.2IgG1ADCCBA1105FcADCC BA1201PD-L1/TGF- BA1201PD-L1CTGF-IIPD-L1PD-L1/PD-1TGF-/TGF-RIIPD-L1 BA1106IL-2CD25 BA1106CD25CD25CD25BA1106CD25FcIL-2BA1106 BA1106(ADCC)TregTBA1106PD-1BA1106IL-2TregBA1106Nature PortfolioScientific Reports •20232BA1106I BA21014(IL-4R)IgG4 BA21011IL-4R(CSU)(COPD)Th2 IL-4IL-13Th2IgETh241 IL-4RTh2BA2101BA21014121BA2101Th2 •20232BA2101I BA1301Claudin 18.2ADC BA1301Claudin 18.2Claudin 18.2 •20231BA1301IND6I BA1202CEA/CD3 BA1202TCD3CEACEA/CD3T BA1202CEATCD3FcCRSTCEA •20235BA1202IND8I A 1.® 2.BA11022024 3.LY-CovMabCOVID-19LY-CovMabCOVID-19SARS-CoV-2IILY-CovMab 18A.08(3) ®® 18.4%261.220226 30220.7®® 20236 3039 20236 302001,900 20231®®® T-cell EngagerADC 20236 30285 20236 303045 (Nature)(Cell Discovery)Antibody Therapeutics(Cancer Communications)13 CMC CMCCMC 33,504.11,7008,00020236 30383 CMC 202342023 20231®5®® 202010 28BA910120215 31BA910120233BA9101IIIBA9101 20235GenCircle™ dsDNAGenCircle™ dsDNADNAGMPGenCircle™ dsDNASTEALTH CAR-T™ReceptorTAC™ 202212 302023 ® ® 4BA1102BA5101 BA9101 BA11043®BA6101BA1102 ®2,000 BA1102BA6101 BA5101 20236 30261.220226 30220.740.518.4%®(BA1101) 20236 30103.039.4%202263033.3%20236 302023 20236 30158.220226 3010.97.4% 20236 301.720226 3013.511.887.4% 20226 3037.620236 3026.620226 302023 20236 30117.120226 30100.816.316.2% 20236 30126.020226 3043.12022III 20236 306.320226 306.6 20236 300.2 20236 30119.520226 30153.3 2023 20236 30250.0202212 31233.516.57.1%20236 30140.120221231375.0234.962.6%202212311.8020236 301.27 20236 30286.4202212 31293.320236 30202212 312021250.02026520236 3031.31.62%2.02% 101.4185.02023630 20236 30 20236 30 20236 30179.6 20236 30 20236 30202212 3120.7%21.9% 212.2202212 31236.4 20236 3074520226 3063120236 3085.120226 3068.4 20236 305% 20236 30 20232 1720233 31 20235 2920234 262181920238 1 20236 30 20236 3020226 30 202212 30H152.8202212 1920236 30 20236 30 C.2.1 20236 30 20236 30 20236 30 241020236 30 13.51(2)(a)(e)(g) 20236 30XVXV78352 1.21,415,5484,720,0006,800,000 2.11,268,4881,800,0001,000,000 3.14,954,6322,480,0003,000,000 4.20232 12 20236 30XV(i)352(ii) 20236 30XV23336 1.Luye HKLuye HKLuye HK 2.LuYe Investment35.42%LuYe InvestmentLuye Life SciencesLuYe InternationalLuye HoldingsLuye Life SciencesNelumbo70%NelumboGinkgoGinkgoShoreaLuYe InvestmentLuYeInternationalLuye Holdings Luye Life Sciences Nelumbo Ginkgo Shorea 20236 30XV23336 Ernst & Young27/F, One Taikoo Place979 King’s RoadQuarry Bay, Hong Kong ࡋ؍㫵嬴㍳з⥽۱௚࢔每欧ࢅਸ਼छଳ垹ןՎⵐ▲ڇ㶣 304820236 30343434 2410 34 20238 27 1,615,1911,730,888 1. 20236 3034202212 31 2. 202212 31 171717179 1 281212 (a)1220231 1 (b)820231 1 2. (c)121220221 120221 1 (i)(ii)20221 1 2. (c) 12202320226 30 (d)1220231 1202312 31 3. 4. 5. 6. 7. 20236 3020226 30 8. 509,278,0942022498,583,294 202320226 30 9. 621,000202212 31661,000 20236 3048,910,000202212 3149,527,0009 9. 10. 90 20236 308,194,000202212 317,160,000 11. 212,232,00020221231236,353,000 12. *20226 30GeneLeap Biotech(c)(a)GeneLeap Biotech 12. 12. (b) 20236 30225,266,000202212 31 (c) 12. (d) 13. 13. 20236 30 20236 30202212 31 20226 30 13.